Sigma supports biomedical technologies across multiple therapeutic indications with scientific, medical, and market alignment.
Harmonizing every phase of the development lifecycle to mitigate regulatory, clinical, budget, and timeline risks.
We support Class II and III device programs requiring strong translational alignment from development through market readiness.
Diagnostic technologies demand early integration of clinical utility, regulatory classification, and validation strategy.
AI-enabled technologies represent a new area of MedTech requiring delicate regulatory navigation and lifecycle governance.
As former directors and executives of mid to large-size CROs, we are able to effectively advise and guide Sponsors through:
We support market-facing strategies that strengthen adoption, reimbursement, lifecycle evidence, and long-term growth.
